Jason Rhodes Sells Shares of Dyne Therapeutics

On June 25, 2026, Jason Rhodes sold 24,100 shares of Dyne Therapeutics, Inc. (NasdaqGS: DYN) at an average price of $21.10 per share. This transaction, which was planned, amounted to a total value of $508,510.

Insider Buying and Selling at Dyne Therapeutics, Inc.

Jason Rhodes wasn't the only insider moving shares in June. On June 24, he sold an additional 95,900 shares at $21.02 each. On June 23, Rhodes sold 147,760 shares at $21.13 per share. Dirk Kersten also sold shares, offloading 73,286 shares at $21.05 on June 23 and another 190,676 shares at $20.57 on June 22. Barry Greene, however, bought 57,463 shares on June 22, though the purchase price wasn't specified.

Other Institutional Activity in Dyne Therapeutics

Several institutional investors have also been active in Dyne Therapeutics. T. Rowe Price Investment Management, Inc. significantly increased its holdings by 13,245,712 shares, reaching a total of 30,785,801 shares valued at about $558.1 million, a 75.5% increase. Janus Henderson Group PLC reduced its stake by 240,346 shares, ending with 13,647,376 shares worth approximately $247.4 million, a decrease of 1.7%. BlackRock, Inc. added 509,032 shares to its holdings, bringing its total to 11,699,870 shares valued at $212.1 million, a 4.5% increase. FMR LLC also grew its position by 2,339,059 shares, holding a total of 8,908,980 shares valued at $161.5 million, marking a 35.6% increase.

Dyne Therapeutics, Inc. Stock Down 16.5%

Shares of Dyne Therapeutics traded near $20.61 on Friday. The company has a market capitalization of about $3.41 billion. It is not currently profitable, which means it has no meaningful P/E ratio. The stock's 52-week range spans from $8.06 to $25.00, with a 50-day moving average of $18.39 and a 200-day moving average of $17.81. Dyne Therapeutics has a high current ratio of 19.92, indicating strong liquidity, and a quick ratio of 18.97. Its debt-to-equity ratio stands at 19.50.

Analysts Set New Price Targets

Analysts have been active in setting targets for Dyne Therapeutics. On May 15, 2026, Evercore ISI Group maintained a buy rating with a $33.00 price target. Bernstein also maintained a hold rating with a $24.00 target on May 13, 2026. Earlier in the year, Chardan Capital and Morgan Stanley both maintained buy ratings, with targets of $38.00 and $47.00, respectively. The consensus among analysts remains a strong buy, with a target mean price of $38.25 based on 16 opinions.

About Dyne Therapeutics

Dyne Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for neuromuscular diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy. The company utilizes its FORCE platform to deliver disease-modifying therapeutics aimed at muscle diseases. Under the leadership of CEO John G. Cox, Dyne Therapeutics employs approximately 263 people.

Bottom Line

Jason Rhodes' recent share sales in Dyne Therapeutics are part of a planned transaction strategy. Investors and analysts closely watch insider activity as it can signal confidence or strategic shifts within a company. While these insider actions provide insights, they are just one piece of the broader investment puzzle. Keep in mind that 13F filings and insider reports are backward-looking and reflect past actions.